Observational Study Suggests Continuing ACE-I/ARBs in Patients with Declining kidney Function May Reduce Cardiovascular Risk Without Increased Risk of Progression to End-stage Kidney Disease

Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate – JAMA Internal Medicine (free for a limited period)

Editorial: Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving (free for a limited period)

Related Commentary on Twitter

Continuing ACE-I/ARB in patients with declining kidney function may provide cardiovascular and survival benefits without excessive harm of ESKD. https://t.co/h74imGHRbv

— JAMA Internal Medicine (@JAMAInternalMed) March 9, 2020